BioSpace News Archive

Avalo Therapeutics, Inc. announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will participate in the SVB Securities Therapeutics Forum being held Tuesday, July 11th – Wednesday, July 12th, 2023 in New York, NY.

ResMed announced it plans to release financial and operational results for the fourth quarter of fiscal year 2023 on Thursday, August 3, 2023, after the New York Stock Exchange closes.

Mersana Therapeutics, Inc. announced that on July 3, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 38,775 shares of its common stock and restricted stock unit awards to acquire an aggregate of 82,260 shares of its common stock, to 5 new employees whose employment commenced in June 2023.

Astria Therapeutics, Inc., a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 60,000 shares of Astria’s common stock on July 3, 2023 under Astria’s 2022 Inducement Stock Incentive Plan.

OSE Immunotherapeutics SA announced that the trial’s Independent Drug Safety Monitoring Board provided a positive recommendation on the continuation until its completion of the Phase 2 clinical trial of IL-7 Receptor antagonist Lusvertikimab in ulcerative colitis.

Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has communicated that it has completed patient enrollment for the Hexvix® Phase III bridging trial.

Extendicare Inc. announced that it plans to release its financial results for the second quarter of 2023 after market close on Thursday, August 10, 2023.

Metrion Biosciences Limited announced the appointments of Dr Robert Kirby to Chief Operating Officer and Dr Edward Stevens to Chief Scientific Officer.

Genesis MedTech announced that its ArtiSential™, a revolutionary series of articulating laparoscopic instruments, has successfully obtained approval from the China’s National Medical Products Administration for market release.

LIfT BioSciences, (‘LifT’ or ‘the Company’), a rapidly emerging biotech company bringing to market a first-in-class allogeneic innate cell therapy, today announced successful proof-of-concept production of its patented cancer killing alpha neutrophils from induced pluripotent stem cells (iPSCs).